Overview
A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2024-09-30
2024-09-30
Target enrollment:
Participant gender: